Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Vandana Singh

Hookipa Shares Jump On New Preclinical Data On Cancer Immunotherapies

HOOKIPA Pharma Inc (NASDAQ:HOOK) has announced preclinical data demonstrating potent T cell responses, combination use beyond PD-1 inhibitors, and the ability to break immune tolerance to various self-antigens for targeting cancers. 

  • Preclinical data show that combining co-stimulatory 4-1BB agonists with arenaviral immunotherapy increased tumor control and resulted in a higher cure rate than arenaviral immunotherapy alone. 
  • Combining arenaviral immunotherapy with a 4-1BB agonistic antibody resulted in complete tumor rejection in 30% of mice following treatment. 
  • Improved tumor control and cure rates of up to 50% were also observed with a 4-1BB ligand integrated into the arenaviral vector.
  • A separate preclinical analysis offered additional evidence of potential combination with other modalities. In this analysis, replicating arenaviral immunotherapy was sequentially combined with adoptively transferred TCR transgenic T cells, which resulted in tumor cures in all mice receiving combination therapy, with 100% survival at the end of the experiment (60 days after administration).
  • These preclinical data further support the clinical entry of HOOKIPA's HB-300 candidate for prostate cancer. The company intends to submit an Investigational New Drug (IND) application in Q3 of 2022.
  • Price Action: HOOK shares are up 11.8% at $1.98 during the market session on the last check Wednesday.
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.